Pancreas-derived mesenchymal stromal cells share immune response-modulating and angiogenic potential with bone marrow mesenchymal stromal cells and can be grown to therapeutic scale under Good Manufacturing Practice conditions

Thirlwell, K. L., Colligan, D., Mountford, J. C., Samuel, K., Bailey, L., Cuesta-Gomez, N., Hewit, K. D., Kelly, C. J., West, C. C., McGowan, N. W., Casey, J. J., Graham, G. J., Turner, M. L., Forbes, S. and Campbell, J. D.  Pancreas-derived mesenchymal stromal cells share immune response-modulating and angiogenic potential with bone marrow mesenchymal…

Read More

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine Conjugated Antibody–Drug Conjugate Targeting 5T4

Harper, Lloyd, Dimasi, Toader, Marwood, Lewis, Bannister, Jovanovic, Fleming, d’Hooge, Mao, Marrero, Korade, Strout, Xu, Chen, Wetzel, Breen, van Vlerken-Ysla, Jalla, Rebelatto, Zhong, Hurt, Hinrichs, Huang, Howard, Tice, Hollingsworth, Herbst, Kamal. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine Conjugated Antibody–Drug Conjugate Targeting 5T4. Mol Cancer Ther; 16(8) August 2017. DOI: 10.1158/1535-7163.MCT-16-0825

Read More